Copyright Reports & Markets. All rights reserved.

Global Immuno-Oncology Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Immuno-Oncology by Type
    • 1.3.1 Overview: Global Immuno-Oncology Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Immuno-Oncology Consumption Value Market Share by Type in 2025
    • 1.3.3 Immune Checkpoint Inhibitors
    • 1.3.4 Cytokine-Based Immunotherapy
    • 1.3.5 Cancer Vaccines
    • 1.3.6 CAR-T Cell Therapy
    • 1.3.7 Others
  • 1.4 Global Immuno-Oncology Market by Application
    • 1.4.1 Overview: Global Immuno-Oncology Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospitals
    • 1.4.3 Drugstores
    • 1.4.4 Others
  • 1.5 Global Immuno-Oncology Market Size & Forecast
  • 1.6 Global Immuno-Oncology Market Size and Forecast by Region
    • 1.6.1 Global Immuno-Oncology Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Immuno-Oncology Market Size by Region, (2021-2032)
    • 1.6.3 North America Immuno-Oncology Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Immuno-Oncology Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Immuno-Oncology Market Size and Prospect (2021-2032)
    • 1.6.6 South America Immuno-Oncology Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Immuno-Oncology Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Bristol-Myers Squibb
    • 2.1.1 Bristol-Myers Squibb Details
    • 2.1.2 Bristol-Myers Squibb Major Business
    • 2.1.3 Bristol-Myers Squibb Immuno-Oncology Product and Solutions
    • 2.1.4 Bristol-Myers Squibb Immuno-Oncology Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Bristol-Myers Squibb Recent Developments and Future Plans
  • 2.2 Merck & Co., Inc.
    • 2.2.1 Merck & Co., Inc. Details
    • 2.2.2 Merck & Co., Inc. Major Business
    • 2.2.3 Merck & Co., Inc. Immuno-Oncology Product and Solutions
    • 2.2.4 Merck & Co., Inc. Immuno-Oncology Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Merck & Co., Inc. Recent Developments and Future Plans
  • 2.3 Roche AG
    • 2.3.1 Roche AG Details
    • 2.3.2 Roche AG Major Business
    • 2.3.3 Roche AG Immuno-Oncology Product and Solutions
    • 2.3.4 Roche AG Immuno-Oncology Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Roche AG Recent Developments and Future Plans
  • 2.4 AstraZeneca, Plc
    • 2.4.1 AstraZeneca, Plc Details
    • 2.4.2 AstraZeneca, Plc Major Business
    • 2.4.3 AstraZeneca, Plc Immuno-Oncology Product and Solutions
    • 2.4.4 AstraZeneca, Plc Immuno-Oncology Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 AstraZeneca, Plc Recent Developments and Future Plans
  • 2.5 Sanofi S.A.
    • 2.5.1 Sanofi S.A. Details
    • 2.5.2 Sanofi S.A. Major Business
    • 2.5.3 Sanofi S.A. Immuno-Oncology Product and Solutions
    • 2.5.4 Sanofi S.A. Immuno-Oncology Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Sanofi S.A. Recent Developments and Future Plans
  • 2.6 Dendreon Pharmaceuticals
    • 2.6.1 Dendreon Pharmaceuticals Details
    • 2.6.2 Dendreon Pharmaceuticals Major Business
    • 2.6.3 Dendreon Pharmaceuticals Immuno-Oncology Product and Solutions
    • 2.6.4 Dendreon Pharmaceuticals Immuno-Oncology Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Dendreon Pharmaceuticals Recent Developments and Future Plans
  • 2.7 Novartis
    • 2.7.1 Novartis Details
    • 2.7.2 Novartis Major Business
    • 2.7.3 Novartis Immuno-Oncology Product and Solutions
    • 2.7.4 Novartis Immuno-Oncology Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Novartis Recent Developments and Future Plans
  • 2.8 Gilead Sciences Inc.
    • 2.8.1 Gilead Sciences Inc. Details
    • 2.8.2 Gilead Sciences Inc. Major Business
    • 2.8.3 Gilead Sciences Inc. Immuno-Oncology Product and Solutions
    • 2.8.4 Gilead Sciences Inc. Immuno-Oncology Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Gilead Sciences Inc. Recent Developments and Future Plans
  • 2.9 Merck KGaA
    • 2.9.1 Merck KGaA Details
    • 2.9.2 Merck KGaA Major Business
    • 2.9.3 Merck KGaA Immuno-Oncology Product and Solutions
    • 2.9.4 Merck KGaA Immuno-Oncology Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Merck KGaA Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Immuno-Oncology Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Immuno-Oncology by Company Revenue
    • 3.2.2 Top 3 Immuno-Oncology Players Market Share in 2025
    • 3.2.3 Top 6 Immuno-Oncology Players Market Share in 2025
  • 3.3 Immuno-Oncology Market: Overall Company Footprint Analysis
    • 3.3.1 Immuno-Oncology Market: Region Footprint
    • 3.3.2 Immuno-Oncology Market: Company Product Type Footprint
    • 3.3.3 Immuno-Oncology Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Immuno-Oncology Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Immuno-Oncology Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Immuno-Oncology Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Immuno-Oncology Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Immuno-Oncology Consumption Value by Type (2021-2032)
  • 6.2 North America Immuno-Oncology Market Size by Application (2021-2032)
  • 6.3 North America Immuno-Oncology Market Size by Country
    • 6.3.1 North America Immuno-Oncology Consumption Value by Country (2021-2032)
    • 6.3.2 United States Immuno-Oncology Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Immuno-Oncology Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Immuno-Oncology Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Immuno-Oncology Consumption Value by Type (2021-2032)
  • 7.2 Europe Immuno-Oncology Consumption Value by Application (2021-2032)
  • 7.3 Europe Immuno-Oncology Market Size by Country
    • 7.3.1 Europe Immuno-Oncology Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Immuno-Oncology Market Size and Forecast (2021-2032)
    • 7.3.3 France Immuno-Oncology Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Immuno-Oncology Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Immuno-Oncology Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Immuno-Oncology Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Immuno-Oncology Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Immuno-Oncology Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Immuno-Oncology Market Size by Region
    • 8.3.1 Asia-Pacific Immuno-Oncology Consumption Value by Region (2021-2032)
    • 8.3.2 China Immuno-Oncology Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Immuno-Oncology Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Immuno-Oncology Market Size and Forecast (2021-2032)
    • 8.3.5 India Immuno-Oncology Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Immuno-Oncology Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Immuno-Oncology Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Immuno-Oncology Consumption Value by Type (2021-2032)
  • 9.2 South America Immuno-Oncology Consumption Value by Application (2021-2032)
  • 9.3 South America Immuno-Oncology Market Size by Country
    • 9.3.1 South America Immuno-Oncology Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Immuno-Oncology Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Immuno-Oncology Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Immuno-Oncology Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Immuno-Oncology Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Immuno-Oncology Market Size by Country
    • 10.3.1 Middle East & Africa Immuno-Oncology Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Immuno-Oncology Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Immuno-Oncology Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Immuno-Oncology Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Immuno-Oncology Market Drivers
  • 11.2 Immuno-Oncology Market Restraints
  • 11.3 Immuno-Oncology Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Immuno-Oncology Industry Chain
  • 12.2 Immuno-Oncology Upstream Analysis
  • 12.3 Immuno-Oncology Midstream Analysis
  • 12.4 Immuno-Oncology Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Immuno-Oncology market size was valued at US$ 67110 million in 2025 and is forecast to a readjusted size of US$ 171940 million by 2032 with a CAGR of 14.6% during review period.
    Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body"s own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
    The industry"s leading producers are Bristol-Myers Squibb, Merck & Co and Roche AG, with revenues of 27.89%, 22.10% and 20.85%, respectively, in 2019.
    This report is a detailed and comprehensive analysis for global Immuno-Oncology market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Immuno-Oncology market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Immuno-Oncology market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Immuno-Oncology market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Immuno-Oncology market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Immuno-Oncology
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Immuno-Oncology market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc., Merck KGaA, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Immuno-Oncology market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Immune Checkpoint Inhibitors
    Cytokine-Based Immunotherapy
    Cancer Vaccines
    CAR-T Cell Therapy
    Others
    Market segment by Application
    Hospitals
    Drugstores
    Others
    Market segment by players, this report covers
    Bristol-Myers Squibb
    Merck & Co., Inc.
    Roche AG
    AstraZeneca, Plc
    Sanofi S.A.
    Dendreon Pharmaceuticals
    Novartis
    Gilead Sciences Inc.
    Merck KGaA
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Immuno-Oncology product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Immuno-Oncology, with revenue, gross margin, and global market share of Immuno-Oncology from 2021 to 2026.
    Chapter 3, the Immuno-Oncology competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Immuno-Oncology market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Immuno-Oncology.
    Chapter 13, to describe Immuno-Oncology research findings and conclusion.

    Buy now